Method for treating a perioheral arterial disease
US-2024425576-A1 · Dec 26, 2024 · US
Anti-CCL17 antibodies
US9944697B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9944697-B2 |
| Application number | US-201414534525-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 6, 2014 |
| Priority date | Nov 6, 2013 |
| Publication date | Apr 17, 2018 |
| Grant date | Apr 17, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
First claim
Opening claim text (preview).
We claim: 1. An isolated antibody specifically binding human CCL17 comprising a heavy chain complementarity determining region (HCDR) 1, a HCDR2 and a HCDR3 and a light chain complementarity determining region (LCDR) 1, a LCDR2 and a LCDR3 of SEQ ID NOs: 4, 5, 42, 8, 24 and 28, respectively. 2. The antibody of claim 1 , wherein the antibody comprises the heavy chain variable region (VH) of SEQ ID NO: 46 and the light chain variable region (VL) of SEQ ID NO: 62. 3. The antibody of claim 1 , wherein the antibody is human or humanized. 4. The antibody of claim 3 , wherein the antibody is of IgG1, IgG2, IgG3, or IgG4 isotype. 5. The antibody of claim 4 , wherein the antibody comprises a substitution in an Fc region. 6. The antibody of claim 5 , wherein the substitution comprises V234A, G237A, P238S, H268A, V309L, A330S or P331S substitution on IgG2, or S228P, L23A or L235A substitution on IgG4, wherein residue numbering is according to the EU Index. 7. The antibody of claim 6 , wherein the substitution comprises V234A/G237A/P238S/H268A/V309L/A330S/P331S substitution on IgG2 or S228P/L234A/L235A substitution on IgG4, wherein residue numbering is according to the EU Index. 8. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically accepted carrier.
Assignees
Inventors
Classifications
Cytokines; Lymphokines; Interferons · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
- C07K16/24Primary
against cytokines, lymphokines or interferons · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9944697B2 cover?
- The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
- Who is the assignee on this patent?
- Janssen Biotech Inc, Jansson Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/24. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).